GLP-1 (SM)

GLP-1 receptor agonists are long-acting analogues of glucagon-like peptide-1, an incretin released from intestinal L-cells after a meal. Native GLP-1 is degraded by dipeptidyl peptidase-4 within about two minutes, so every research-grade analogue in this class carries substitutions and usually a fatty-acid chain that confers albumin binding and extends the half-life from minutes to days.

This item is listed under a coded site name rather than the compound name. If you need the specific molecular identity confirmed before ordering, research support will provide it along with the Certificate of Analysis for the current batch.

Receptor-level work covers GLP-1 receptor binding and the downstream cAMP and PKA signalling that follows, in pancreatic beta-cell lines and in transfected systems. Physiological strands cover glucose-dependent insulin secretion, gastric emptying, and central appetite signalling through hypothalamic and hindbrain GLP-1 receptor populations.

The reason this class matters as a research baseline is that it is single-target. Dual and triple agonists are evaluated against it, so a study comparing receptor coverage needs the single-receptor comparator to make the comparison mean anything. The metabolic research peptides hub sets out how this group divides.

Supplied lyophilised. Long acylated incretin analogues are more robust than short peptides in the dry state but are prone to aggregation in solution, particularly after agitation or repeated freeze-thaw, and aggregates are not recoverable by filtration without losing material.

Reconstitute gently against the vial wall, avoid shaking, and prepare working solutions fresh rather than cycling one vial. Solvent options are under reconstitution supplies.